Evidence map›Paper›PMID 41878057›Full record

ArticleFrontiers in pharmacology2025

hnRNP A2B1 as a promising therapeutic target for radiomodulatory drug development: evidence from computational and experimental studies.

N S Lubinets, I S Tonkii, V A Sazonova, K Dutta, A E Putintseva, O O Volkova, E V Skorb, P Zun, A Ruzov, V Yu Kravtsov and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

N S LubinetsDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
I S TonkiiDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
V A SazonovaDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
K DuttaDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
A E PutintsevaSt. Petersburg National Research Academic University of the Russian Academy of Sciences named after Z.I. Alferov, Saint-Petersburg, Russia.
O O VolkovaDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
E V SkorbDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
P ZunDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
A RuzovInstitute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia.
V Yu KravtsovDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.
S ShityakovDepartment of Chemoinformatics, ITMO University, Saint-Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation modulation is critical due to the growing risks of radiation exposure in medical, occupational, and environmental settings. This study explored the potential of heterogeneous nuclear ribonucleoproteins (hnRNPs), particularly hnRNP A2B1, as therapeutic targets for radiomodulatory drugs.

Indexed as

hesperidinheterogeneous nuclear ribonucleoproteinshnRNP A2B1molecular dockingpsoralidinradiomodulating drugsradiomodulators

Identifiers

PMID41878057
PMCPMC13006754

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.